Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The
pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH) …

Objective To review the current state of the literature regarding the socioeconomics of atopic
dermatitis (AD)—more specifically how socioeconomic status (SES) affects AD risk and how …

Background On the basis of safety data for patients with inflammatory rheumatism or
inflammatory bowel disease, treatment with Janus kinase (JAK) inhibitors (JAKi) has been …

Background The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been
defined in clinical trials, but no real-world data are currently available. We aimed to assess …

Severe atopic dermatitis, which affects both adults and children, is a debilitating disorder
with a significant decline of patients' quality of life. Although aetiopathogenic factors are …

Background Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, and
there is increasing evidence that the interleukin (IL)‐36 pathway may play a role in the …

Atopic dermatitis (AD) is chronic, pruritic, inflammatory skin disease that affects a significant
portion of the population in industrialized nations. For nonresponders to conventional …

Atopic dermatitis (AD) was once thought to be primarily a pediatric disease that remitted with
increasing age. However, recent epidemiologic studies showed that AD is a common and …

Background Atopic dermatitis (AD) is a chronic, inflammatory skin disorder characterised by
intense itch and eczematous lesions. Rising prevalence of AD has been observed …

Abstract Interleukin-4 (IL-4) is a pleiotropic cytokine mainly known for its role in type 2
immunity. Therapies antagonizing or blocking IL-4 activity have been developed to …